On May 8, 2014, Pozen, Inc. (NASDAQ:POZN) reported financial results for the first quarter ended March 31, 2014. Total revenues in the fourth quarter were $7.5 million, comprised of $4.5 million in royalties on $34 million in sales of Vimovo at Horizon Pharma (NASDAQ:HZNP) in the U.S. and $19 million in sales at AstraZeneca (NYSE:AZN) outside the U.S., and $3.0 million in licensing revenue relating to amortization of the $15 million upfront payment from Sanofi U.S. on the PA licensing agreement in September 2013. Revenues for quarter were up 703% from the first quarter 2013 and absolutely crushed our expectations of $5.0 million - with all the upside coming from higher royalties on Vimovo....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|